Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Kate Rawson
Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).
Revamped Office of New Drugs will create many new opportunities for FDA to promote from within. But FDA may also need to recruit from outside for candidates to take on management roles. While that is not typical, there are successful examples.
FDA reaches final stages of reorganization that will better distribute an ever-increasing review workload; recent high-level departures will make filling even more management slots difficult.